한글목차

암/종양 프로파일링 세계 시장은 2030년까지 198억 달러에 이를 전망

2023년에 103억 달러로 추정되지만/종양 프로파일링 세계 시장은 2023-2030년간 CAGR 9.8%로 성장하여 2030년에는 198억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 면역측정 기술은 CAGR 9.3%를 나타내고, 분석 기간 종료시에는 62억 달러에 이를 것으로 예측됩니다. 차세대 시퀀싱 기술 분야의 성장률은 분석 기간중 CAGR 10.8%로 추정됩니다.

미국 시장은 37억 달러로 추정, 중국은 CAGR 10.6%로 성장 예측

미국의 암/종양 프로파일링 시장은 2023년에 37억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 16억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2023-2030년간 CAGR은 10.6%입니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 8.7%와 9.2%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 9.9%를 나타낼 전망입니다.

세계 암/종양 프로파일링 시장 - 주요 동향 및 촉진요인 요약

유전체학 및 차세대 염기서열 분석(NGS)을 통한 분자 프로파일링의 등장은 맞춤형 암 치료에 혁명을 일으키고 있습니다. 분자 프로파일링은 조직 샘플과 저침습적 액체 생검을 사용하여 개인 맞춤형 암 치료에 매우 중요한 유전자 돌연변이 및 융합을 식별합니다. 최근 포르말린 고정 파라핀 포매(FFPE) 조직에 DNA/RNA 시퀀싱을 적용함으로써 종양 내 작용 표적을 정확히 찾아내는 능력이 크게 향상되었습니다. 그러나 치료 가능한 표적이 있다고 해서 그것이 반드시 질병의 진행이나 임상적 효과에 관여하는 것은 아닙니다. 효과적인 분자 프로파일링을 위해서는 고도의 기술력과 종양 생물학 및 관련 치료에 대한 깊은 이해가 필요하며, 특히 NGS가 대체 치료 옵션을 제공하는 표준화된 치료법이 없는 경우 더욱 그러합니다.

종양 프로파일링은 암의 유전적 배경에 대한 종합적인 통찰력을 제공하여 특정 유전자 변이를 표적으로 하는 표적 치료법 개발을 촉진합니다. 이 접근법은 폐암 치료에 큰 변화를 가져왔으며, EGFR 돌연변이를 표적으로 하는 치료법은 가장 빠른 성공 사례 중 하나입니다. 프로파일링은 개별 돌연변이를 정확히 찾아낼 뿐만 아니라 암의 진행과 내성 메커니즘의 광범위한 분자적 틀을 밝혀내어 내성을 퇴치하기 위한 병용요법의 길을 열어줍니다. 또한, 프로파일링을 통한 바이오마커의 식별은 면역요법에 대한 환자의 반응을 예측하고 보다 맞춤화된 치료 요법을 가능하게 하며, ctDNA 및 CTC 분석과 같은 액체생검 기술의 통합은 프로파일링 능력을 더욱 향상시켜 종양 동태 및 미세잔존병변의 비침습적 실시간 모니터링을 가능하게 합니다. 비침습적 실시간 모니터링이 가능합니다.

암/종양 프로파일링 시장의 성장은 분자 프로파일링 기술의 발전, 액체 생검의 채택 확대, AI와 머신러닝의 통합 등 여러 요인에 의해 촉진될 것으로 예상됩니다. 단일 세포 시퀀싱 기술의 발전은 종양의 이질성에 대한 심층적인 통찰력을 제공하고 질병 진행과 치료 저항성을 유발하는 하위 집단을 식별할 수 있습니다. 이러한 수준의 상세한 정보는 보다 효과적인 치료 전략 수립에 도움이 될 수 있습니다. 또한 AI와 ML은 복잡한 분자 데이터 분석을 강화하여 프로파일링의 정확도를 높이고 환자 결과를 예측할 수 있도록 돕습니다. 이러한 기술의 역량 확대와 임상 통합을 통해 보다 개인화되고 신속한 암 치료가 가능해져 궁극적으로 환자 결과 개선과 종양학 분야의 지속적인 혁신으로 이어질 것으로 기대됩니다.

조사 대상 기업 예(주요 전55개사)

• Caris Life Sciences
• Genomic Health, Inc.
• Helomics Corporation
• HTG Molecular Diagnostics, Inc.
• Illumina, Inc.
• Nanostring Technologies, Inc.
• NeoGenomics Laboratories, Inc.
• Oxford Gene Technology
• Qiagen NV
• Ribomed Biotechnologies, Inc.

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 세계 기타 지역

제4장 경쟁

영문목차

Global Cancer / Tumor Profiling Market to Reach US$19.8 Billion by 2030

The global market for Cancer / Tumor Profiling estimated at US$10.3 Billion in the year 2023, is expected to reach US$19.8 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2023-2030. Immunoassays Technology, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the Next Generation Sequencing Technology segment is estimated at 10.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 10.6% CAGR

The Cancer / Tumor Profiling market in the U.S. is estimated at US$3.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.

Global Cancer / Tumor Profiling Market - Key Trends & Drivers Summarized

The advent of molecular profiling, driven by genomics and next-generation sequencing (NGS), is revolutionizing personalized cancer treatment. By using tissue samples and less invasive liquid biopsies, molecular profiling identifies genetic mutations and fusions that are crucial for personalized cancer therapies. In recent years, the application of DNA/RNA sequencing on formalin-fixed, paraffin-embedded (FFPE) tissues significantly enhanced the ability to pinpoint actionable targets within tumors. Nevertheless, having a druggable target does not necessarily ensure its role in disease progression or clinical efficacy. Effective molecular profiling necessitates advanced technical skills and a profound understanding of tumor biology and associated therapies, especially in cases lacking standardized treatments where NGS provides alternative therapeutic options.

Tumor profiling offers comprehensive insights into the genetic landscape of cancers, facilitating the development of targeted therapies aimed at specific genetic alterations. This approach notably transformed the treatment of lung cancer, with therapies targeting EGFR mutations being among the earliest successful examples. Beyond pinpointing individual mutations, profiling elucidates the broader molecular framework of cancer progression and resistance mechanisms, paving the way for combination therapies to combat resistance. Additionally, the identification of biomarkers through profiling can predict patient responses to immunotherapy, enabling more personalized treatment regimens. The integration of liquid biopsy techniques, such as ctDNA and CTC analysis, further augments profiling capabilities, allowing non-invasive, real-time monitoring of tumor dynamics and minimal residual disease.

The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies. Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.

Select Competitors (Total 55 Featured) -

• Caris Life Sciences
• Genomic Health, Inc.
• Helomics Corporation
• HTG Molecular Diagnostics, Inc.
• Illumina, Inc.
• Nanostring Technologies, Inc.
• NeoGenomics Laboratories, Inc.
• Oxford Gene Technology
• Qiagen NV
• Ribomed Biotechnologies, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Rise in Cancer Incidence Fosters Growth in Cancer / Tumor Profiling Market
  • Select Cancer Statistics
  • Total Number of New Cancer Cases by Type: 2022
  • Total Number of Cancer Deaths by Type: 2022
  • Cancer Incidence by Region: 2022
  • Cancer Mortality by Region: 2022
  • Tumor Profiling: At Zenith of Efforts to Expedite Transition from Histologic to Precision Cancer Treatment
  • Economic Frontiers: Trends, Trials & Transformations
  • In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
  • All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
  • With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
  • Global Market Analysis and Prospects
  • Global Cancer/Tumor Profiling Market Looks Forward to Prolific Growth
  • Genomic Profiling, NGS, Breast Cancer & Research: Thriving Segments of Cancer/Tumor Profiling Market
  • NGS as Primary Technology Segment
  • Breast Cancer & Pharmaceutical Segments to Exhibit Solid Gains
  • Research Rules while Treatment Selection Posts Fastest Growth
  • North America Clinches Commanding Stake on Global Cancer/Tumor Profiling Market
  • Asia-Pacific Emerges as Lucrative Market
  • Pulsating Trends Favoring Expansion of Cancer/Tumor Profiling Market
  • Select Market Drivers
  • Market Opportunities
  • Competitive Landscape: Innovation and R&D Focus amid Fierce Competition
  • Cancer / Tumor Profiling - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Recent Market Activity
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Molecular Profiling Paves the Way for Personalized Cancer Treatment
  • Introduction of Tumour Profiling Techniques Ensures Timely Treatment for Cancer Patients
  • Application of Cancer/Tumor Profiling in Cancer Research Sees Significant Growth
  • Transformative Advances in Tumor Profiling Technologies Revolutionize Cancer Treatment
  • Liquid Biopsy: A Transformative Tool in Cancer Profiling, Diagnostics, and Monitoring
  • Precision Oncology Holds Upside Potential with Advancements in Multi-Omics Tumor Profiling
  • Leveraging AI and Machine Learning in Tumor Profiling Facilitates Cancer Care
  • Precision Oncology Holds Upside Potential with Advancements in Multi-Omics Tumor Profiling
  • Single-Cell Sequencing: Revolutionizing Cancer Research
  • Tumor Profiling: A Catalyst for Precision Companion Diagnostics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cancer / Tumor Profiling Market Analysis of Annual Sales in US$ Million for Years 2017 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cancer / Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 4: World 13-Year Perspective for Cancer / Tumor Profiling by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2017, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 7: World 13-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 10: World 13-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 13: World 13-Year Perspective for In-Situ Hybridization by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 16: World 13-Year Perspective for Polymerase Chain Reaction by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 19: World 13-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 22: World 13-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 25: World 13-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 28: World 13-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 31: World 13-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 34: World 13-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 37: World 13-Year Perspective for Melanoma Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 40: World 13-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 43: World 13-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 46: World 13-Year Perspective for Clinical Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 49: USA 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 52: USA 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 55: USA 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 58: Canada 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 61: Canada 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 64: Canada 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• JAPAN
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 67: Japan 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 70: Japan 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 73: Japan 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• CHINA
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 76: China 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 79: China 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 82: China 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• EUROPE
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Cancer / Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 85: Europe 13-Year Perspective for Cancer / Tumor Profiling by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2017, 2024 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 88: Europe 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 91: Europe 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 94: Europe 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• FRANCE
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 95: France Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 97: France 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 100: France 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 103: France 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• GERMANY
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 106: Germany 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 109: Germany 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 112: Germany 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• ITALY
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 115: Italy 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 118: Italy 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 121: Italy 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• UNITED KINGDOM
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 122: UK Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 124: UK 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 127: UK 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 130: UK 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 133: Rest of Europe 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 136: Rest of Europe 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 139: Rest of Europe 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• ASIA-PACIFIC
  • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 142: Asia-Pacific 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 145: Asia-Pacific 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 148: Asia-Pacific 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
• REST OF WORLD
  • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Rest of World Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 151: Rest of World 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
  • TABLE 152: Rest of World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Rest of World Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 154: Rest of World 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
  • TABLE 155: Rest of World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Rest of World Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
  • TABLE 157: Rest of World 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030

IV. COMPETITION